Integral Derivatives’s iShares Biotechnology ETF IBB Stock Holding History

Integral Derivatives’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	$256K	Sell	2,400 -2,100	-47%	-$233K	0.01%	548
2017 Q4	$480K	Sell	4,500 -61,500	-93%	-$6.57M	0.01%	729
2017 Q3	$7.34M	Buy	66,000 +30,000	+83%	+$3.21M	0.13%	90
2017 Q2	$3.72M	Sell	36,000 -66,000	-65%	-$6.5M	0.08%	155
2017 Q1	$9.97M	Buy	102,000 +41,400	+68%	+$3.96M	0.18%	58
2016 Q4	$5.36M	Buy	60,600 +55,500	+1,088%	+$5.05M	0.1%	138
2016 Q3	$492K	Buy	5,100 +2,100	+70%	+$200K	0.01%	631
2016 Q2	$257K	Sell	3,000 -3,300	-52%	-$296K	0.01%	780
2016 Q1	$548K	Buy	+6,300	New	+$563K	0.02%	506
2015 Q4	–	Sell	-5,100	Closed	-$516K	–	1133
2015 Q3	$516K	Buy	5,100 +2,700	+113%	+$324K	0.01%	698
2015 Q2	$295K	Sell	2,400 -5,100	-68%	-$611K	0.01%	881
2015 Q1	$859K	Buy	+7,500	New	+$827K	0.02%	551

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Natixis Paris, France $28B AUM 26.79% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Integral Derivatives's IBB Position: Q1 2018 in Review

Integral Derivatives sold out of iShares Biotechnology ETF (IBB) in Q1 2018, closing a stake of 2,839 shares — an estimated $315K sold.

Integral Derivatives first reported a position in IBB in Q2 2014 and held it in 6 quarters. The position peaked at $2.31M in Q3 2017. 608 funds tracked by Wall St. Rank hold IBB as of Q1 2018.

Integral Derivatives reported no remaining iShares Biotechnology ETF position as of Q1 2018 after selling out during the quarter.
Integral Derivatives sold 2,839 iShares Biotechnology ETF shares in Q1 2018, an estimated $315K.
Integral Derivatives first reported a position in iShares Biotechnology ETF in Q2 2014 and held it in 6 quarters.
Integral Derivatives's iShares Biotechnology ETF position peaked at $2.31M in Q3 2017.
608 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.